Bank of Nova Scotia’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $658K | Buy |
5,235
+1,067
| +26% | +$134K | ﹤0.01% | 802 |
|
|
2025
Q1 | $461K | Buy |
4,168
+81
| +2% | +$8.96K | ﹤0.01% | 808 |
|
|
2024
Q4 | $558K | Sell |
4,087
-790
| -16% | -$108K | ﹤0.01% | 828 |
|
|
2024
Q3 | $562K | Sell |
4,877
-9,883
| -67% | -$1.14M | ﹤0.01% | 809 |
|
|
2024
Q2 | $2.03M | Buy |
14,760
+7,514
| +104% | +$1.03M | ﹤0.01% | 629 |
|
|
2024
Q1 | $999K | Sell |
7,246
-970
| -12% | -$134K | ﹤0.01% | 762 |
|
|
2023
Q4 | $1.08M | Buy |
8,216
+1,785
| +28% | +$235K | ﹤0.01% | 760 |
|
|
2023
Q3 | $723K | Sell |
6,431
-2,385
| -27% | -$268K | ﹤0.01% | 755 |
|
|
2023
Q2 | $831K | Sell |
8,816
-118,734
| -93% | -$11.2M | ﹤0.01% | 700 |
|
|
2023
Q1 | $12.9M | Sell |
127,550
-12,768
| -9% | -$1.29M | 0.04% | 244 |
|
|
2022
Q4 | $16.8M | Sell |
140,318
-114,985
| -45% | -$13.7M | 0.04% | 266 |
|
|
2022
Q3 | $27.1M | Buy |
255,303
+243,505
| +2,064% | +$25.9M | 0.09% | 186 |
|
|
2022
Q2 | $1.15M | Sell |
11,798
-487
| -4% | -$47.5K | ﹤0.01% | 813 |
|
|
2022
Q1 | $1.15M | Buy |
12,285
+5,502
| +81% | +$516K | ﹤0.01% | 893 |
|
|
2021
Q4 | $578K | Buy |
+6,783
| New | +$578K | ﹤0.01% | 1032 |
|
|
2021
Q1 | – | Sell |
-5,780
| Closed | -$554K | – | 1060 |
|
|
2020
Q4 | $554K | Buy |
5,780
+697
| +14% | +$66.8K | ﹤0.01% | 848 |
|
|
2020
Q3 | $489K | Buy |
5,083
+976
| +24% | +$93.9K | ﹤0.01% | 860 |
|
|
2020
Q2 | $501K | Buy |
+4,107
| New | +$501K | ﹤0.01% | 746 |
|
|
2019
Q1 | – | Sell |
-71,000
| Closed | -$5.07M | – | 879 |
|
|
2018
Q4 | $5.07M | Buy |
+71,000
| New | +$5.07M | 0.02% | 392 |
|
|
2017
Q4 | – | Sell |
-61,600
| Closed | -$3.78M | – | 933 |
|
|
2017
Q3 | $3.78M | Buy |
61,600
+21,400
| +53% | +$1.31M | 0.02% | 420 |
|
|
2017
Q2 | $1.85M | Buy |
+40,200
| New | +$1.85M | 0.01% | 642 |
|